Swedish image analysis software developer AMRA Medical has added extra participants from the UK Biobank study to its imaging database on body composition profiling.
Through a collaboration with Pfizer and UK Biobank, AMRA was able to grow its database from 10,000 to 25,000 participants and move the company closer to its goal of analyzing the body composition of 100,000 individuals.
The new data provide norms for several metabolic conditions -- such as nonalcoholic fatty liver disease, obesity, and diabetes -- that may serve as references in future clinical trials and clinical practice.
